Therapeutic evaluation
Generic name	Brand name	Indication	Patented medicine prices review board	Prescrire international
Abacavir	Ziagen	HIV/AIDS	Not innovative
Agalsidase alfa	Replagal	Fabry disease	Not innovative
Amprenavir	Agenerase	HIV/AIDS	Innovative
Aztreonam for inhalation solution	Cayston	cystic fibrosis	Not innovative
Bortezomib	Velcade	multiple myeloma	Not innovative
Crizotinib	Xalkori	lung cancer		Not innovative
Dasatinib	Sprycel	chronic myeloid leukemia	Not evaluated
Deferasirox	Exjade	thalassemia	Innovative
Delavirdine	Rescriptor	HIV/AIDS	Not innovative
Gefitinib	Iressa	lung cancer	Innovative
Idebenone	Catena	Friedreich's ataxia	Not innovative
Imatinib	Gleevec	gastrointestinal tumour	Not innovative
Lenalidomide	Revlimid	anaemia due to myelodysplastic syndrome	Not innovative
Memantine	Ebixa	Alzheimer disease	Not innovative
Nelarabine	Atriance	leukemia	Not innovative
Nesiritide	Natrecor	congestive heart failure	Not innovative
Nevirapine	Viramune	HIV/AIDS	Not innovative
Nilotinib	Tasigna	chronic myeloid leukemia	Not innovative
Panitumumab	Vectibix	colorectal cancer	Not innovative
Raltegravir	Isentress	HIV/AIDS	Innovative
Recombinant factor VIIa	Niastase	clotting disorders	Not innovative
Remestemcel-L	Prochymal	acute graft vs. host disease	Not evaluated
Riluzole	Rilutek	amyotrophic lateral sclerosis	Not innovative
Sorafenib	Nexavar	renal cancer	Not innovative
Sunitnib	Sutent	renal cancer	Not innovative
Tenofovir	Viread	HIV/AIDS	Not innovative
Zanamivir	Relenza	influenza	Innovative